Boston University Libraries OpenBU
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    •   OpenBU
    • BU Open Access Articles
    • BU Open Access Articles
    • View Item
    •   OpenBU
    • BU Open Access Articles
    • BU Open Access Articles
    • View Item

    Epigenetic treatment of neurodegenerative ophthalmic disorders: an eye toward the future.

    Thumbnail
    License
    Copyright Walter H. Moos et al. 2017; Published by Mary Ann Liebert, Inc. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Date Issued
    2017
    Publisher Version
    10.1089/biores.2017.0036
    Author(s)
    Moos, Walter H.
    Faller, Douglas V.
    Glavas, Ioannis P.
    Harpp, David N.
    Irwin, Michael H.
    Kanara, Iphigenia
    Pinkert, Carl A.
    Powers, Whitney R.
    Steliou, Kosta
    Vavvas, Demetrios G.
    Kodukula, Krishna
    Share to FacebookShare to TwitterShare by Email
    Export Citation
    Download to BibTex
    Download to EndNote/RefMan (RIS)
    Metadata
    Show full item record
    Permanent Link
    https://hdl.handle.net/2144/40075
    Version
    Published version
    Citation (published version)
    Walter H. Moos, Douglas V. Faller, Ioannis P. Glavas, David N. Harpp, Michael H. Irwin, Iphigenia Kanara, Carl A. Pinkert, Whitney R. Powers, Kosta Steliou, Demetrios G. Vavvas, Krishna Kodukula. 2017. "Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future.." Biores Open Access, Volume 6, Issue 1, pp. 169 - 181. https://doi.org/10.1089/biores.2017.0036
    Abstract
    Eye disease is one of the primary medical conditions that requires attention and therapeutic intervention in ageing populations worldwide. Further, the global burden of diabetes and obesity, along with heart disease, all lead to secondary manifestations of ophthalmic distress. Therefore, there is increased interest in developing innovative new approaches that target various mechanisms and sequelae driving conditions that result in adverse vision. The research challenge is even greater given that the terrain of eye diseases is difficult to landscape into a single therapeutic theme. This report addresses the burden of eye disease due to mitochondrial dysfunction, including antioxidant, autophagic, epigenetic, mitophagic, and other cellular processes that modulate the biomedical end result. In this light, we single out lipoic acid as a potent known natural activator of these pathways, along with alternative and potentially more effective conjugates, which together harness the necessary potency, specificity, and biodistribution parameters required for improved therapeutic outcomes.
    Rights
    Copyright Walter H. Moos et al. 2017; Published by Mary Ann Liebert, Inc. This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Collections
    • Cancer Center Papers [12]
    • MED: Medicine Papers [241]
    • MED: Biochemistry Papers [27]
    • BU Open Access Articles [4754]


    Boston University
    Contact Us | Send Feedback | Help
     

     

    Browse

    All of OpenBUCommunities & CollectionsIssue DateAuthorsTitlesSubjectsThis CollectionIssue DateAuthorsTitlesSubjects

    Deposit Materials

    LoginNon-BU Registration

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Boston University
    Contact Us | Send Feedback | Help